Canada Markets open in 8 hrs 56 mins

BioVaxys Technology Corp. (BVAXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1000+0.0054 (+5.65%)
At close: 09:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0947
BidN/A x N/A
AskN/A x N/A
Day's Range0.1000 - 0.1118
52 Week Range0.0661 - 0.5040
Avg. Volume75,044
Market Cap9.087M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0540
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Baystreet

    Stocks in play: BioVaxys Technology Corp

    Announced today that Hospices Civils de Lyon, France has agreed to serve as a clinical study site for ...

  • CNW Group

    BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

    BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that Hospices Civils de Lyon, France ("HCL") has agreed to serve as a clinical study site for the Phase I study of BVX-0918, the Company's autologous haptenized tumor cell vaccine for late-stage ovarian cancer. HCL has further agreed to supply BioVaxys with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients undergoing treatment at the hospital to permit the Company to

  • CNW Group

    International Patent Application Filed for Cervical Cancer Vaccine

    BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has continued to expand the patent coverage for its cancer vaccine platform by filing an international patent application through the Patent Cooperation Treaty ("PCT") for broad geographic market coverage outside the US for cervical cancer. BioVaxys has an agreement with Procare Health of Barcelona, Spain ("Procare") for clinical co-development of the Company's autologous bihapteniz